Revlimid Approved With Safeguards Against Fetal Exposure
This article was originally published in The Pink Sheet Daily
Executive Summary
Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.
You may also be interested in...
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis
Study finds that concurrent use of erythropoietin agents with Revlimid and dexamethasone should be minimized.